Post date
04/03/2021
Authorization to start clinical trial in the US granted for rare paediatric bone disease
Mont-Saint-Guibert, Mar 4, 2021 (GlobeNewswire) – Novadip Biosciences (“Novadip”), a clinical stage company
Post date
27/01/2021
Belgium – 27th January 2021 – Syndesi Therapeutics SA, a clinical stage biotechnology company developing novel modulators of the synaptic vesicle protein SV2A for the treatment of cognitive impairment
Post date
20/11/2020
New funding confirms Aphea.Bio’s frontrunner position in sustainable and innovative agriculture
GENT, NOVEMBER 20 - Aphea.Bio, a Belgium-based agtech startup, announced today that it secured a €14
Post date
24/11/2020
Tessares, a young company from Louvain-la-Neuve, has won an ultra-selective European subsidy of 1.2 million euros!
In Europe, more than 40% of homes in rural areas do not have a quality internet
Post date
21/10/2020
ViroVet : Animal health company focused on combatting viral infections in livestock
LEUVEN, Belgium, October 21th, 2020 — ViroVet NV, a leading Belgian biopharmaceutical company active in the
Post date
28/09/2020
Belgium – 28th September 2020 – Syndesi Therapeutics SA, a clinical stage biotechnology company developing novel modulators of the synaptic vesicle protein SV2A for the treatment of cognitive
Post date
05/10/2020
Novadip Biosciences, spin-off of UCLouvain and Cliniques universitaires Saint-Luc (UCLouvain) have achieved a world first in bone reconstruction. Very promising results for the treatment of rare
Post date
10/09/2020
Even when cured, people with Covid-19 have significant sequelae: neurological or cardiovascular disorders, fatigue, loss of respiratory efficiency…
Ath, September 10, 2020 - Botalys has developed a
Post date
02/09/2020
Promethera® Biosciences SA, a global innovator in cell-based medicines and liver diseases, based in Wallonia, Belgium, today announced that John Tchelingerian, PhD, has resigned from his position as
Post date
29/07/2020
Mont-Saint Guibert, Belgium, 29 July, 2020: Novadip Biosciences ("Novadip" or "the Company"), a clinical-stage biopharmaceutical company leveraging its unique tissue regeneration technology platform
Post date
23/07/2020
CAMBRIDGE, Mass. and GOSSELIES, Belgium, July 23, 2020 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development
Post date
02/07/2020